Results 221 to 230 of about 86,737 (312)

Allele specific expression in Alzheimer's disease

Alzheimer's &Dementia, Volume 22, Issue 6, June 2026.
Abstract INTRODUCTION Allele‐specific expression (ASE), preferential expression of one allele at a heterozygous locus, is implicated in various brain diseases but remains largely uncharacterized in Alzheimer's disease (AD). METHODS We performed a genome‐wide characterization of ASE variants across seven brain regions of 2,231 AD and Control patients ...
Zishan Wang, Delowar Hossain, Judy Jiaru Wang, Varun R. Subramaniam, Bin Zhang, Minghui Wang, Kuan‐lin Huang   +6 more
wiley   +1 more source

Olive Components (Biophenols or Polyphenols) in Neurodegenerative Disease Models and Clinical Studies: A Systematic Review of Evidence and Translational Barriers. [PDF]

Biomedicines
Omar SH, Ghani MA.
europepmc   +1 more source

Mapping cross‐domain drivers of Alzheimer's disease risk through integrated network analysis

Alzheimer's &Dementia, Volume 22, Issue 6, June 2026.
Abstract INTRODUCTION Alzheimer's disease (AD) is a complex neurodegenerative disorder with numerous known risk factors. Identification of which genetic factors are causal drivers is difficult due to the long disease prodrome in an inaccessible organ.
Gregory A Cary, Stephen Keegan, Jesse C Wiley, Jake Gockley, Robert R Butler III, Frank M Longo, Allan I Levey, Anna K Greenwood, Karina Leal, Gregory W Carter, for The Emory‐Sage‐SGC‐JAX TREAT‐AD Center   +10 more
wiley   +1 more source

HDL‐mimetic peptide treatment reverses APOE4‐induced transcriptomic and lipidomic alterations in the brain of humanized APOE mice

Alzheimer's &Dementia, Volume 22, Issue 6, June 2026.
Abstract INTRODUCTION The apolipoprotein E4 (APOE4) allele is the strongest genetic risk factor for late‐onset Alzheimer's disease (AD). ApoE4 has reduced lipidation capacity and impaired lipid transport, disrupting neuronal maintenance. The high‐density lipoprotein (HDL)‐mimetic peptide 4F offers a potential therapeutic strategy.
Allison Chang, Minwoo Kim, Matthew Glittenberg, Wenhui Qu, Danni Li, Ling Li   +5 more
wiley   +1 more source

Zolpidem restores sleep and decreases amyloid in a mouse model. [PDF]

Alzheimers Dement
Yu L, Yokomizo S, Doan TH, Zhao Q, Ganne A, Balasubramaniam M, Kastanenka KV.   +6 more
europepmc   +1 more source

Stable neuronal representations underlie cognitive resilience to Alzheimer's disease pathology

Alzheimer's &Dementia, Volume 22, Issue 6, June 2026.
Abstract INTRODUCTION While Alzheimer's disease (AD) typically elicits progressive cognitive decline, some individuals with significant AD pathology maintain cognition. Understanding the neuronal underpinnings of such cognitive resilience would propel the development of interventions for delaying dementia.
Keying Chen, Emma Pineau, Margaret Koletar, Andrea Trevisiol, Jack Simiao He, Mary Hill, Maged Goubran, John Sled, JoAnne McLaurin, Bojana Stefanovic   +9 more
wiley   +1 more source

A High-Throughput Assay for Monitoring and Quantifying Amyloid-β Accumulation and Clearance in Alzheimer's Disease Cell Models. [PDF]

J Neurochem
Ariyath A, Arigo FD, Fyfe A, Fernando WMADB, Martins R, Bharadwaj P.   +5 more
europepmc   +1 more source

Early microglial response to amyloid plaques drives sleep loss in Alzheimer's disease

Alzheimer's &Dementia, Volume 22, Issue 6, June 2026.
Abstract INTRODUCTION Sleep disruption is an early feature of Alzheimer's disease (AD), but the cellular mechanisms linking amyloid pathology to sleep loss remain unclear. METHODS Electroencephalography/electromyography (EEG/EMG) recordings, quantitative EEG analysis, and sleep deprivation were performed in APPswe/PSEN1dE9 (APP/PS1) mice at different ...
Nicholas J. Constantino, Riley E. Irmen, Matthew J. Lanning, Sierra M. Turner, Clair C. Ashley, Caitlin M. Carroll, Evan M. Neary, Dave Rubinow, J. Andy Snipes, Shannon L. Macauley   +9 more
wiley   +1 more source

Redirecting Alzheimer's disease therapeutics: Multitarget drugs and complementary non‐pharmacological strategies

Alzheimer's &Dementia, Volume 22, Issue 6, June 2026.
Abstract Alzheimer's disease (AD) is a multifactorial neurodegenerative disorder driven by intersecting pathological processes. Persistent attrition in AD drug‐development pipelines highlights the limited clinical impact of single‐target therapies and has increased interest in multi‐target approaches acting on shared biological hubs.
Humberto Martínez‐Orozco, Jesús Andrade‐Guerrero, Nelly Jovana Pastén‐Castrejón, Chryslaine Rodríguez‐Tanty, Sofía Y Diaz‐Miranda   +4 more
wiley   +1 more source